The Coalition will work to improve the quality of life and health of patients with rare diseases.
The Coalition is working to ensure a predictable framework for medical treatment, when such treatment is available. We believe this contributes to improving the quality of life and health of patients with rare diseases. The Coalition currently consists of the biotech companies Amicus, BioMarin, Chiesi, Sanofi and UCB.
Since its inception in 2015, the Coalition's aim has been to work to ensure better framework conditions for medical care for patients with rare diseases. The Coalition does this through political participation, external and internal events and through media visibility.
Since its inception, the Coalition has enjoyed good cooperation with several actors in the field of rare diseases. On the clinical side, the National Competence Services for Rare Diagnoses and the Norwegian Association for Medical Genetics are important discussion partners, and of the patient organizations, the Norwegian Disabled People's Association (FFO) is important to the Coalition.